Surge in counterfeit drug-incidents increases the need for EU-barcodes
A change is on the way in the European pharmaceutical industry. It is called coding and is going to help avert counterfeiting scandals, such as the recent Avastin controversy in the US. But it is going to be costly for the companies.
af LEONORA BECK
Worldwide reports of counterfeit drugs have increased more than ten-fold from 2002 to 2010. The surge also leads to an increase in the risk of counterfeit drugs infiltrating Europe’s legal distribution system.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
